https://openbell.ai/ 2026-11-15T04:35:18.025Z hourly 1.0 https://openbell.ai/support 2026-11-15T04:35:18.025Z monthly 0.7 https://openbell.ai/privacy 2026-11-15T04:35:18.025Z monthly 0.5 https://openbell.ai/terms 2026-11-15T04:35:18.025Z monthly 0.5 https://openbell.ai/feed.json 2026-11-15T04:35:18.025Z hourly 0.8 https://openbell.ai/news/ADIG:1794708165000 2026-11-15T02:02:45.000Z daily 0.9 https://cdn.brandfetch.io/ADIG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Law Firms Initiate Investigations into ADI Global Distribution Inc. Following Goodwill Impairment Disclosure ADI Global Distribution disclosed a $659 million noncash goodwill impairment on November 12, 2026, and reported a $655 million net loss for the third quarter. The impairment was attributed to lower projected earnings and cash flows, along with declines in the company’s stock price and market capitalization, and equaled about 62% of the goodwill balance reported in its August 13 Form 10-Q. On November 13, law firms including Levi & Korsinsky and Kirby McInerney announced investigations into whether ADI or its senior management made materially false or misleading statements about goodwill and the business outlook. https://openbell.ai/news/STUB:1794708160000 2026-11-15T02:02:40.000Z daily 0.9 https://cdn.brandfetch.io/STUB/w/400/h/400?c=1idopYfmtR7ZKg8QMud StubHub Raises Full-Year Gross Merchandise Sales Outlook StubHub raised its full-year gross merchandise sales outlook to $10.3 billion from its previous forecast of $10.1 billion, citing updated expectations for its secondary ticketing marketplace. The report did not provide profit figures or details on stock-price movements. https://openbell.ai/news/DV:1794708158000 2026-11-15T02:02:38.000Z daily 0.9 https://cdn.brandfetch.io/DV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nielsen Announces Financing Plans for Acquisition of DoubleVerify Holdings, Inc. Nielsen said it plans to fund its acquisition of DoubleVerify Holdings with proceeds from new term loan borrowings, investor equity contributions, and available cash. The announcement outlines the transaction’s financing strategy; no purchase price, financial results, or market reaction was reported. https://openbell.ai/news/ASTS:1794708131000 2026-11-15T02:02:11.000Z daily 0.9 https://cdn.brandfetch.io/ASTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud AST SpaceMobile Reports Q3 2026 Financial Results and Strategic Updates AST SpaceMobile reported Q3 2026 revenue of $42.3 million and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share. It ended the quarter with approximately $3.2 billion in cash, cash equivalents and restricted cash, and maintained its 2026 revenue guidance of $150 million to $200 million. The company secured $1.0 billion in non-dilutive funding from Japan’s Ministry of Internal Affairs and Communications for midband satellite manufacturing and launches, and announced Blacklift, a 20-ton reusable rocket intended to deploy BlueBird satellites beginning in late 2028. AST SpaceMobile also said its dual-use satellite program received a U.S. priority DPAS rating. https://openbell.ai/news/ZBAO:1794704528000 2026-11-15T01:02:08.000Z daily 0.9 https://cdn.brandfetch.io/ZBAO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Zhibao Technology Reports Fiscal Year 2026 Financial Results and Files Annual Report on Form 20-F Zhibao Technology reported fiscal 2026 revenue of RMB 319.9 million (US$47.1 million), up 16% year over year and in line with preliminary guidance. Operating income was RMB 9.2 million, compared with an operating loss of RMB 53.5 million in fiscal 2025, while net loss narrowed 95.3% to RMB 2.9 million. After the fiscal year, the company disclosed a US$154.7 million private placement and a definitive agreement to acquire NEXSYS TECH SDN. BHD. to expand its international capabilities. https://openbell.ai/news/AZN:1794690089000 2026-11-14T21:01:29.000Z daily 0.9 https://cdn.brandfetch.io/AZN/w/400/h/400?c=1idopYfmtR7ZKg8QMud FDA Approves AstraZeneca's Imfinzi for Muscle-Invasive Bladder Cancer The FDA approved AstraZeneca’s Imfinzi (durvalumab) with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi alone after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval adds a treatment option for this patient group; the article reports no financial figures or stock-price impact. https://openbell.ai/news/MRL:1794686529000 2026-11-14T20:02:09.000Z daily 0.9 https://cdn.brandfetch.io/MRL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Merlin Properties Raises 2026 FFO Guidance and Updates Data Center Strategy Merlin Properties raised its 2026 funds from operations (FFO) guidance to EUR 0.58 per share. The company also updated its strategy for its 704 MW data center portfolio; the report did not provide further details on the changes or any stock-price impact.